STRAUMANN HOLDING AG 
Webcast for investors, analysts and media
Basel, 30 April, 2024
1
1
This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.
2
2
Highlights | Guillaume Daniellot |
Financials | Yang Xu |
Recent achievements & strategy | Guillaume Daniellot |
Outlook 2024 | Guillaume Daniellot |
Q&A and upcoming events | Guillaume Daniellot, Yang Xu |
3
3
Guillaume Daniellot, CEO
4
4
Revenue in CHF | Organic revenue growth1 | Regional performance | |
644m | 15.1% | China | |
dynamic demand in most of our business | or 8.1% in CHF | exceptional organic growth boosted by | |
segments | continued strong momentum and low | ||
comparison base | |||
Implantology | Orthodontics | Outlook 20242 confirmed | |
iExcel | ClearPilot 8.0 | High single-digit | |
organic revenue growth | |||
high-performance premium implant system | ClearCorrect further improved its value | profitability at around 26% at constant 2023 | |
launched in North America | proposition | currency rates, or between 24% and 25% | |
including expected FX headwind | |||
5 | 1 Organic growth excluding FX and M&A effects 2 Barring unforeseen events | ||
5 |
NAM | EMEA | ||||||
Q1 | 5.2% | ||||||
Q1 | 3.7% | ||||||
Q1 23 | 9.2% | ||||||
Q1 23 | 7.2% | ||||||
44%* | |||||||
28%* | GROUP | ||||||
20%* | |||||||
LATAM | 8%* | APAC | |||||
Q1 | 11.5% | Q1 | 82.0% | ||||
Q1 23 | 20.0% | Q1 23 | -23.5% | ||||
6 * % of Group total revenue | |||||||
6 |
Yang Xu, Chief Financial Officer
7 | |||||||||||
+8.1% | +15.1% | Regional % share of | |||||||||
organic growth | |||||||||||
59 | 5 | 644 | Organic | 6 | LATAM | ||||||
7 | NAM | ||||||||||
17 | EMEA | ||||||||||
596 | |||||||||||
14 | 6 | ||||||||||
7 | 559 | ||||||||||
-43 | 70 | APAC | |||||||||
Change in organic growth | |||||||||||
+5.2% | +3.7% | +82.0% | +11.5% | ||||||||
Net Revenue | FX effect* | M&A effect | Adjusted | EMEA | NAM | APAC | LATAM | Net Revenue | Q1 2024 | ||
Q1 2023 | Revenue base | Q1 2024 | |||||||||
8 * applying 2024 FX rates | |||||||||||
8 |
Tooth replacement | Tooth alignment | Digital solutions |
and restoration | ||
9
9
Guillaume Daniellot, CEO
10
10
6 | |||||||
5.3 | 5.3 | ||||||
5 | |||||||
4 | |||||||
2.7 | 2.9 | ||||||
3 | |||||||
2.4 | |||||||
2 | |||||||
0.7 | |||||||
1 | |||||||
>50% | ~5% | ~5% | <5% | ||||
>15% | ~15% | ||||||
0 | |||||||
Premium | Non-premium ClearAligner | Regeneratives CADCAM | CADCAM | ||||
Implantology | Implantology | equipment | prosthetics | ||||
Market size | Market share | ||||||
in CHF bn | |||||||
11 Source: Straumann Group estimates |
Innovation
Education
Clinical evidence
11
800
700
600
500
400
300
200
100
-
South | Spain | Italy | France | Germany | Brazil | USA | China | AU + NZ UK-Ireland | India |
Korea |
12 Source: Implant volume data Straumann Group estimates, population data from Statista. 1 Assumes 100% of adult population can afford implants
12
new | ||||
13 | 13 | |||
13 | ||||
NAM | EMEA | VALUE IMPLANT MARKET | ||
~31 MILLION IMPLANTS1 | ||||
NAM | EMEA | |||
LATAM | APAC | |||
LATAM | APAC | |||
Straumann Group share | Market opportunity | |||
14 | 1 Straumann Group estimates; market share by end of 2023 | |||
14 |
Software & Platform
Integration
Straumann UI/UX
15
15
CBCT
IOS | Clear Aligner | Smile in a Box | Scan & Shape |
16
16
Technology | Service | Commercialization |
ClearPilot 8.0 | Center in Costa Rica | Ortho Sales Academy |
17
17
Capacity expansion | Technology | People |
Straumann AXS |
Shanghai Campus, China | Digital customer platform | EDGE!UP |
18
18
19
Market environment and assumption
- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- Outgrowing market vs. prior year
20
Revenue and profitability
- Organic revenue growth in the high single-digit percentage range
- Profitability at around 26% at constant 2023 currency rates or between 24% and 25% including expected FX headwind
20
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Straumann Holding AG published this content on 30 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2024 10:04:27 UTC.
